The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype.
作者信息
Schinke Carolina, Hoering Antje, Wang Hongwei, Carlton Victoria, Thanandrarajan Sharmilan, Deshpande Shayu, Patel Purvi, Molnar Gabor, Susanibar Sandra, Mohan Meera, Mathur Pankaj, Radhakrishnan Muthukumar, Hoque Shadiqul, Jo Kamimoto Jorge, Grazziutti Monica, van Rhee Frits, Zangari Maurizio, Insuasti-Beltran Giovanni, Alapat Daisy, Post Ginell, Yaccoby Shmuel, Epstein Joshua, Rasche Leo, Johnson Sarah, Moorhead Martin, Willis Tom, Barlogie Bart, Walker Brian, Weinhold Niels, Davies Faith E, Morgan Gareth J
机构信息
Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Cancer Resarch and Biostatistics, Seattle, WA, USA.
出版信息
Haematologica. 2017 Aug;102(8):e313-e316. doi: 10.3324/haematol.2017.165217. Epub 2017 May 18.
Abstract
摘要
相似文献
1
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype.多发性骨髓瘤中缓解深度的预后价值取决于评估时间、风险状态和分子亚型。
Haematologica. 2017 Aug;102(8):e313-e316. doi: 10.3324/haematol.2017.165217. Epub 2017 May 18.
2
[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].[采用新一代测序评估微小残留病在多发性骨髓瘤中的预后价值]
Nihon Rinsho. 2016 Jul;74 Suppl 5:565-9.
3
Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?多发性骨髓瘤临床实践中是否到了引入微小残留病灶的时候？
Clin Cancer Res. 2015 May 1;21(9):2001-8. doi: 10.1158/1078-0432.CCR-14-2841. Epub 2015 Mar 9.
4
Go with the flow for monitoring response in myeloma with minimal residual disease.顺应潮流，监测多发性骨髓瘤微小残留病的反应。
Leuk Lymphoma. 2008 Feb;49(2):177-8. doi: 10.1080/10428190701824601.
5
Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice.多发性骨髓瘤中的微小残留病监测：流式细胞术是首选方法。
Br J Haematol. 2005 Mar;128(5):732-3; author reply 733-4. doi: 10.1111/j.1365-2141.2005.05376.x.
6
[Interpretation of minimal residual disease monitoring for response evaluation in "the guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)"].《解读<中国多发性骨髓瘤诊断与治疗指南（2020年修订版）>中微小残留病监测用于疗效评估》
Zhonghua Nei Ke Za Zhi. 2020 May 1;59(5):332-334. doi: 10.3760/cma.j.cn112138-20200217-00084.
7
Myeloma minimal residual disease testing in the United States: Evidence of improved standardization.美国骨髓瘤微小残留病检测：标准化改善的证据
Am J Hematol. 2016 Dec;91(12):E502-E503. doi: 10.1002/ajh.24540. Epub 2016 Oct 11.
8
Deep Response in Multiple Myeloma: A Critical Review.多发性骨髓瘤的深度缓解：一项批判性综述
Biomed Res Int. 2015;2015:832049. doi: 10.1155/2015/832049. Epub 2015 Dec 10.
9
A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma.一种用于检测骨髓瘤微小残留病的单管六色流式细胞术筛查检测方法。
Leukemia. 2007 Sep;21(9):2046-9. doi: 10.1038/sj.leu.2404815. Epub 2007 Jul 26.
10
Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma.定量 ASO-PCR 评估的反应深度可预测多发性骨髓瘤干细胞移植后的结果。
Eur J Haematol. 2010 Nov;85(5):416-23. doi: 10.1111/j.1600-0609.2010.01510.x.
引用本文的文献
1
Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.基于证据的韩国多发性骨髓瘤临床管理指南：解决12个关键临床问题。
Blood Res. 2025 Feb 4;60(1):9. doi: 10.1007/s44313-025-00055-9.
2
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.适合移植的骨髓瘤患者中下一代测序微小残留病灶（MRD）和 PET 扫描的综合分析。
Blood Cancer J. 2023 Mar 6;13(1):32. doi: 10.1038/s41408-023-00794-x.
3
Plasma cell neoplasms and related entities-evolution in diagnosis and classification.浆细胞肿瘤及相关疾病——诊断和分类的演变。
Virchows Arch. 2023 Jan;482(1):163-177. doi: 10.1007/s00428-022-03431-3. Epub 2022 Nov 21.
4
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.成熟淋巴细胞肿瘤国际共识分类：临床咨询委员会报告。
Blood. 2022 Sep 15;140(11):1229-1253. doi: 10.1182/blood.2022015851.
5
Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications.多发性骨髓瘤患者的微小残留病评估：影响重大的微小疾病
Front Oncol. 2022 Jan 26;11:801851. doi: 10.3389/fonc.2021.801851. eCollection 2021.
6
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.多发性骨髓瘤患者完全缓解后的纵向微小残留病灶评估——来自 EMN02/HO95 MM 试验中 NMSG 流式微小残留病灶子研究的结果。
BMC Cancer. 2022 Feb 5;22(1):147. doi: 10.1186/s12885-022-09184-1.
7
Minimal residual disease in multiple myeloma: why, when, where.多发性骨髓瘤的微小残留病：为何、何时、何地。
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):37-45. doi: 10.1182/hematology.2021000230.
8
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.使用传统风险模型、PET-CT进行局灶性病变评估以及微小残留病状态来预测复发多发性骨髓瘤的进展风险。
Haematologica. 2021 Dec 1;106(12):3215-3218. doi: 10.3324/haematol.2021.278779.
9
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma.多发性骨髓瘤骨髓微小残留病灶阴性丢失的临床意义。
Blood Adv. 2022 Feb 8;6(3):808-817. doi: 10.1182/bloodadvances.2021005822.
10
Minimal Residual Disease in Multiple Myeloma: Something Old, Something New.多发性骨髓瘤中的微小残留病：旧貌新颜。
Cancers (Basel). 2021 Aug 27;13(17):4332. doi: 10.3390/cancers13174332.
本文引用的文献
1
Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma.剂量密集和剂量强度较低的总疗法5用于基因表达谱定义的高危多发性骨髓瘤。
Blood Cancer J. 2016 Sep 16;6(9):e471. doi: 10.1038/bcj.2016.85.
2
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.微小残留病与多发性骨髓瘤患者更好的生存结果的关联：一项荟萃分析。
JAMA Oncol. 2017 Jan 1;3(1):28-35. doi: 10.1001/jamaoncol.2016.3160.
3
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
4
Clinical value of molecular subtyping multiple myeloma using gene expression profiling.利用基因表达谱分析对多发性骨髓瘤进行分子亚型分型的临床价值
Leukemia. 2016 Feb;30(2):423-30. doi: 10.1038/leu.2015.309. Epub 2015 Nov 3.
5
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.骨髓瘤自体干细胞移植后的微小残留病：对预后的影响独立于诱导方案。
Haematologica. 2016 Feb;101(2):e69-71. doi: 10.3324/haematol.2015.128215. Epub 2015 Oct 15.
6
Curing myeloma at last: defining criteria and providing the evidence.最终治愈骨髓瘤：界定标准并提供证据。
Blood. 2014 Nov 13;124(20):3043-51. doi: 10.1182/blood-2014-07-552059. Epub 2014 Oct 7.
7
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.多参数流式细胞术检测多发性骨髓瘤微小残留病：对 MRC 骨髓瘤 IX 研究结果的影响。
J Clin Oncol. 2013 Jul 10;31(20):2540-7. doi: 10.1200/JCO.2012.46.2119. Epub 2013 Jun 3.
8
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.深度测序技术在急性淋巴细胞白血病微小残留病灶检测中的应用。
Blood. 2012 Dec 20;120(26):5173-80. doi: 10.1182/blood-2012-07-444042. Epub 2012 Oct 16.
9
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.一项卡非佐米联合来那度胺和低剂量地塞米松作为多发性骨髓瘤一线治疗的 1/2 期研究。
Blood. 2012 Aug 30;120(9):1801-9. doi: 10.1182/blood-2012-04-422683. Epub 2012 Jun 4.
10
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.多发性骨髓瘤的总治疗 3 方案：VTD 维持成分（硼替佐米、沙利度胺和地塞米松）累积剂量和过早停药的预后意义，与治疗的所有阶段相关。
Blood. 2010 Aug 26;116(8):1220-7. doi: 10.1182/blood-2010-01-264333. Epub 2010 May 25.
Zotero 插件